Thursday April 18, 2024 | Last Update: April 18, 2024 EDT
Bristol-Myers Squibb Company has announced that it has granted an exclusive right to acquire Promedior, Inc., a clinical stage immunotherapy company pioneering the development of targeted therapeutics to treat fibrotic diseases, for about $1.25 billion, according to a press release issued by Bristol-Myers Squibb.
Read more >>
Just In
Most Read
1
2
3
4
5